A Phase 3 Study to Investigate the Efficacy and Safety of SHR0302 With Moderately to Severely Active Ulcerative Colitis
Status:
Recruiting
Trial end date:
2025-03-31
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind, placebo-controlled, multicenter Phase 3 study that will
enroll approximately 368 subjects aged 18 to 75 years old with Moderately to Severely Active
Ulcerative Colitis.